OncoCyte Corp (NYSEAMERICAN:OCX) Receives Consensus Rating of “Buy” from Brokerages

Shares of OncoCyte Corp (NYSEAMERICAN:OCX) have been given a consensus recommendation of “Buy” by the six research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $4.38.

A number of research analysts have commented on the stock. Piper Sandler raised their price target on shares of OncoCyte from $5.40 to $7.50 and gave the stock an “overweight” rating in a research note on Thursday, June 25th. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price target on shares of OncoCyte in a report on Wednesday, June 17th. Chardan Capital lowered shares of OncoCyte from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $7.75 to $2.00 in a report on Tuesday. Zacks Investment Research lowered shares of OncoCyte from a “hold” rating to a “sell” rating in a report on Tuesday, June 16th. Finally, Lake Street Capital reduced their price target on shares of OncoCyte from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday.

In other OncoCyte news, major shareholder Broadwood Partners, L.P. acquired 1,050,000 shares of the business’s stock in a transaction on Friday, April 24th. The stock was purchased at an average price of $2.24 per share, with a total value of $2,352,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC bought a new stake in shares of OncoCyte during the 1st quarter worth approximately $26,000. Two Sigma Investments LP bought a new position in OncoCyte in the 1st quarter valued at approximately $32,000. Perkins Capital Management Inc. bought a new position in OncoCyte in the 1st quarter valued at approximately $53,000. Oxford Asset Management LLP bought a new position in OncoCyte in the 4th quarter valued at approximately $64,000. Finally, JPMorgan Chase & Co. lifted its stake in OncoCyte by 31.9% in the 1st quarter. JPMorgan Chase & Co. now owns 36,905 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 8,933 shares during the last quarter.

Shares of NYSEAMERICAN OCX traded down $1.44 during mid-day trading on Tuesday, hitting $1.79. The company had a trading volume of 4,594,089 shares, compared to its average volume of 364,631. OncoCyte has a 12 month low of $1.50 and a 12 month high of $3.51.

OncoCyte (NYSEAMERICAN:OCX) last released its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.02). The company had revenue of $0.02 million for the quarter.

About OncoCyte

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Read More: Green Investing

Analyst Recommendations for OncoCyte (NYSEAMERICAN:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.